REHOVOT, Israel and JERSEY CITY, New Jersey, November 3 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics, announced today it will present at AACR's centennial conference "Translational Cancer Medicine 2008: Bridging the Lab and Clinic in Cancer Medicine" Molecular Diagnostics in Cancer Therapeutic Development conference. The event will take place between November 3-6, at the ICC Jerusalem International Convention Center, in Jerusalem, Israel.
MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.
Founded in 2000, the company's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to the
discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong IP position and proprietary platform technologies,
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved